GSK plc GSK announced that the European Medicines Agency has accepted its marketing authorization application (MAA) seeking approval of its investigational ileal bile acid transporter (“IBAT”) ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

Bharat Biotech has partnered with GSK to develop a Shigellosis vaccine. The altSonflex1-2-3 candidate is one of the most ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form ...

GSK PLC closed 16.45% below its 52-week high of £16.79, which the company reached on September 9th.

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Bharat Biotech and GSK collaborate to develop a vaccine for Shigellosis, a severe form of bacterial diarrhea. The innovative ...